Physician profile
Jose Sanchez
NPI 1356428916
$5,215.44
in general payments reported to CMS, 2019-2025
26 companies · $520 in 2025
The $520 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $265 · 2021: $1,124 · 2022: $737 · 2023: $251 · 2024: $690 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.01 | 2022-2025 | Qulipta, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $613.16 | 2021 | |
| Amgen INC. | $560.70 | 2019-2022 | |
| Genentech USA, INC. | $483.15 | 2019-2025 | Tecentriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.28 | 2019-2023 | Relistor |
| Neurocrine Biosciences, INC. | $258.35 | 2024-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $232.65 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.71 | 2019-2024 | Hyqvia |
| Mdd US Operations, LLC | $134.80 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.05 | 2022 | |
| Daiichi Sankyo INC. | $131.94 | 2019 | |
| Orexo US, INC. | $125.03 | 2019 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Lilly USA, LLC | $124.87 | 2025 | Kisunla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $123.50 | 2021 | |
| Agios Pharmaceuticals, INC. | $122.31 | 2024 | Pyrukynd |
| Celgene Corporation | $109.73 | 2019 | |
| Forte Bio-Pharma LLC | $105.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.65 | 2022 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Indivior INC. | $70.12 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $57.92 | 2019 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Allergan, INC. | $27.66 | 2020 | |
| Medtronic, INC. | $19.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.